An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3； (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.本發明以日本人中FOXM1高表現的多樣癌患者約30%為對象，藉由鑑定自forkhead box M1(FOXM1)產生的胜肽，與HLA-A2結合，可活化傷害癌細胞的殺手T細胞，提供一種可作為癌症免疫療法的方法。本發明提供以下(A)或(B)記載的胜肽：(A)由序列編號1至3任一氨基酸序列之胜肽；(B)包含序列編號1至3任一氨基酸序列之胜肽中，有一或數個氨基酸經取代、缺失、插入及/或增加，顯示細胞傷害性(殺手)T細胞誘導活性之胜肽。
